• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Breath Analyzer Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

    12/1/20 8:27:51 AM ET
    $ABT
    $TMO
    $AKER
    $DGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $ABT alert in real time by email

    New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Breath Analyzer Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993415/?utm_source=GNW
    pylori Infection Detection, and Tuberculosis Detection), by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19

    The Global Breath Analyzer Market is expected to grow from USD 1,432.85 Million in 2019 to USD 3,418.97 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 15.59%.

    Market Segmentation & Coverage:
    This research report categorizes the Breath Analyzer to forecast the revenues and analyze the trends in each of the following sub-markets:

    Based on Technology, the Breath Analyzer Market studied across Fuel Cell Technology, Infrared and Smart Crystal, and Semiconductor Oxide Sensor Technology.

    Based on Application, the Breath Analyzer Market studied across Alcohol Detection, Asthma Detection, Drug Abuse Detection, H.pylori Infection Detection, and Tuberculosis Detection.

    Based on End User, the Breath Analyzer Market studied across Government and Private Work, Hospitals and Health Centers, and Law Enforcement Agencies.

    Based on Geography, the Breath Analyzer Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

    Company Usability Profiles:
    The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Breath Analyzer Market including Abbott Laboratories, AK GlobalTech Corporation, Akers Biosciences, Inc., CMI Inc., Drägerwerk AG & Co. KGaA, Intoximeters, Inc., Quest Diagnostics Incorporated, Quest Products, Inc., and Thermo Fisher Scientific Inc..

    FPNV Positioning Matrix:
    The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breath Analyzer Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

    Competitive Strategic Window:
    The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

    Cumulative Impact of COVID-19:
    COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

    The report provides insights on the following pointers:
    1. Market Penetration: Provides comprehensive information on the market offered by the key players
    2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
    3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
    4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
    5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

    The report answers questions such as:
    1. What is the market size and forecast of the Global Breath Analyzer Market?
    2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breath Analyzer Market during the forecast period?
    3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breath Analyzer Market?
    4. What is the competitive strategic window for opportunities in the Global Breath Analyzer Market?
    5. What are the technology trends and regulatory frameworks in the Global Breath Analyzer Market?
    6. What are the modes and strategic moves considered suitable for entering the Global Breath Analyzer Market?
    Read the full report: https://www.reportlinker.com/p05993415/?utm_source=GNW

    About Reportlinker
    ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

    __________________________

    Clare: [email protected]
    US: (339)-368-6001
    Intl: +1 339-368-6001

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $TMO
    $AKER
    $DGX

    CompanyDatePrice TargetRatingAnalyst
    Abbott Laboratories
    $ABT
    4/22/2026$92.00Outperform → Neutral
    Daiwa Securities
    Thermo Fisher Scientific Inc
    $TMO
    3/27/2026$610.00Buy
    DZ Bank
    Quest Diagnostics Incorporated
    $DGX
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    Thermo Fisher Scientific Inc
    $TMO
    12/11/2025$660.00Neutral → Buy
    Citigroup
    Thermo Fisher Scientific Inc
    $TMO
    12/9/2025$685.00Buy
    Goldman
    Thermo Fisher Scientific Inc
    $TMO
    12/8/2025$750.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Thermo Fisher Scientific Inc
    $TMO
    12/2/2025$670.00Overweight
    Morgan Stanley
    Thermo Fisher Scientific Inc
    $TMO
    12/1/2025$670.00Hold → Buy
    HSBC Securities
    More analyst ratings

    $ABT
    $TMO
    $AKER
    $DGX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $TMO
    $AKER
    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President & CFO Samad Sam was granted 108 shares, increasing direct ownership by 0.32% to 33,376 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    4/24/26 6:24:49 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.32% to 15,247 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    4/24/26 6:24:34 PM ET
    $DGX
    Medical Specialities
    Health Care

    Director Gregg Vicky B was granted 68 shares, increasing direct ownership by 0.40% to 17,172 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    4/24/26 6:24:12 PM ET
    $DGX
    Medical Specialities
    Health Care

    $ABT
    $TMO
    $AKER
    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Abbott Labs downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Abbott Labs from Outperform to Neutral and set a new price target of $92.00

    4/22/26 7:52:11 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DZ Bank initiated coverage on Thermo Fisher with a new price target

    DZ Bank initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $610.00

    3/27/26 8:52:59 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    $ABT
    $TMO
    $AKER
    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABT
    $TMO
    $AKER
    $DGX
    SEC Filings

    View All

    $ABT
    $TMO
    $AKER
    $DGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Thermo Fisher Scientific Reports First Quarter 2026 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026. First Quarter Highlights First quarter revenue grew 6% to $11.01 billion. First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43. First quarter adjusted EPS grew 6% to $5.44. Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This includ

    4/23/26 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

    First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

    4/21/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

    Data show how a multi-biomarker class approach improves early-stage cancer detectionAACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCEDABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test. Additionally, the AACR Cancer Prevention Research Award for Outstanding Journal Article will recognize a publication on MCED multiyear outcomes from the DETECT-A

    4/17/26 3:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Abbott Laboratories

    S-8 - ABBOTT LABORATORIES (0000001800) (Filer)

    4/24/26 4:06:32 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    4/23/26 6:03:39 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 10-Q filed by Quest Diagnostics Incorporated

    10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    4/22/26 4:12:53 PM ET
    $DGX
    Medical Specialities
    Health Care

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $ABT
    $TMO
    $AKER
    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $ABT
    $TMO
    $AKER
    $DGX
    Financials

    Live finance-specific insights

    View All

    Thermo Fisher Scientific Reports First Quarter 2026 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026. First Quarter Highlights First quarter revenue grew 6% to $11.01 billion. First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43. First quarter adjusted EPS grew 6% to $5.44. Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This includ

    4/23/26 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

    First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

    4/21/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

    First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE:ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.First-quarter GA

    4/16/26 7:30:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $TMO
    $AKER
    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care